Esophageal cancer
Conditions
Interventions
Docetaxel 70 mg / m2 day 1 Cisplatin 70 mg / m2 day 1 Fluorouracil 750 mg / m2 / day days 1 - 5 Three courses every 3 weeks above Followed by esophagectomy + D 2 or more lymph node dissection
Sponsors
Nagoya University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.ECOG PS 0-1 2.Endoscopic biopsy of esophageal primary lesion histologically diagnosed as squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma or basal cell carcinoma. 3. Any of the following based on TNM classification (UICC-TNM 7 th edition) 1) cStage IB 2) cStage II 3) cStage III Infiltration into the trachea at the cervical /cervical chest boundary (T4) is eligible. Excluding other T4. So-called borderline-resectable T4 disease, not clearly diagnosed as T4, is eligible. 4) cStage IV with supraclavicular lymph node metastasis and without other distant metastasis. 4. Adequate organ function.
Exclusion criteria
Exclusion criteria: 1) Clear T4 other than invasion of cervical / cervical gastrointestinal tract esophageal cancer 2) Distant metastasis to other than supraclavicular lymph nodes. 3) Esophagogastric junction lesion of which main lesion is located in the stomach rather than the esophagus. 4) Judged not to be eligible by the researchers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Histopathological response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Curative resection rate, response rate in preoperative therapy, histopathological complete response rate, rate of adverse events during preoperative therapy, rate of perioperative complications, rate of late complications, rate of serious adverse events, progression-free survival, and overall survival | — |
Countries
Japan
Contacts
Public ContactOsamu Maeda
Nagoya University Hospital Department of Clinical Oncology and Chemotherapy
Outcome results
None listed